Key Highlights
• Integrated BioPharma (OTC: INBP) extended its $4,000,000 revolving credit line with PNC Bank to April 14, 2027.
• The company added a $250,000 convertible line of credit for equipment and vehicle purchases.
• Interest on the convertible facility is set at daily one-month SOFR plus 250 basis points (2.50%) before conversion.
• The agreement was finalized on June 30, 2026, amending a 2025 loan arrangement.
Credit Line Extension Announced
Integrated BioPharma (OTC: INBP) has secured an extension for its revolving credit facility, pushing the expiration to April 2027. The move follows an amendment to a 2025 loan agreement with PNC Bank, maintaining the existing $4,000,000 borrowing capacity. The extension provides continued financial flexibility for the healthcare company’s operations.
New Convertible Facility Added
Alongside the extension, Integrated BioPharma established a $250,000 convertible line of credit. This facility is designated for equipment and vehicle acquisitions, offering additional liquidity for capital expenditures. The terms allow for conversion under conditions agreed upon with PNC Bank.
Interest Rate Structure
The convertible facility carries an interest rate tied to daily one-month SOFR plus 250 basis points, equating to a 2.50% spread. After the conversion date, the rate may shift to a fixed option at the bank’s discretion. This structure aligns with current market conditions while providing cost predictability.
Agreement Timeline
The amendment was executed on June 30, 2026, updating the original loan documents dated April 15, 2025. The revised terms reflect Integrated BioPharma’s ongoing relationship with PNC Bank and its strategic financing needs. No changes were made to the $4,000,000 revolving credit limit.
Borrower and Lender Details
The agreement involves Integrated BioPharma and its wholly owned subsidiary, Manhattan Drug Company. PNC Bank remains the sole lender for both the extended revolving credit and the new convertible facility. The arrangement supports the company’s broader financial strategy in the healthcare sector.
Regulatory Compliance
The transaction was disclosed in accordance with the Securities Exchange Act of 1934. Integrated BioPharma filed the necessary documentation to ensure transparency for investors and regulators. The filing underscores the company’s adherence to financial reporting standards.
Market Implications
The extended credit line and new facility could enhance Integrated BioPharma’s operational capacity. Investors may view the move as a sign of strengthened liquidity, though the impact on stock performance will depend on execution. The healthcare sector continues to monitor financing trends closely.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...